Floatz logo

Alpelisib

Advanced Malignant Solid Neoplasm

National Cancer Institute (NCI)Small moleculePhase 2Active
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
81/ 100

Competitive context

123 Active assets in the Advanced Malignant Solid Neoplasm cohort.

Asset / SponsorPhaseRating
Olaparib
National Cancer Institute (NCI)
Phase 2BB
Nivolumab
National Cancer Institute (NCI)
Phase 2BB
Palbociclib
National Cancer Institute (NCI)
Phase 2BB
Carboplatin
OHSU Knight Cancer Institute
Phase 2B
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 2B

View all 50 →

Same molecule, other indications

Alpelisib is also rated in:

triple-negative breast carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
HER2 positive breast carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
Sickle Cell AnemiaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →